What Is the Fair Value of Johnson & Johnson (JNJ) Stock? Intrinsic Value Analysis
Quick Answer
Based on a comprehensive intrinsic value analysis utilizing multiple valuation models in July 2026, Johnson & Johnson (JNJ) is currently overvalued.
While the company's underlying fundamentals remain robust—highlighted by a raised 2026 revenue guidance midpoint of $101.1 billion and strong oncology sales—the current stock price of $252 has outpaced its intrinsic value. Our blended fair value estimate for JNJ stock sits in the $190.00 to $199.00 range. At 21.6x forward earnings, the stock is trading at a significant premium to its historical averages, suggesting that investors are paying a steep price for the company's safety and recent earnings beats.
Current Stock Price & Valuation
As of mid-July 2026, Johnson & Johnson's market pricing reflects high expectations following a strong second-quarter earnings report.
- Current Stock Price: $252.00 Johnson & Johnson (JNJ) - Sure Dividend
- Market Capitalization: $606 Billion Johnson & Johnson (JNJ) - Sure Dividend
- Forward P/E Ratio: 21.6x Johnson & Johnson (JNJ) - Sure Dividend
- Dividend Yield: 2.1% Johnson & Johnson (JNJ) - Sure Dividend
- 2026 Adjusted EPS Guidance: $11.60 to $11.75 (Midpoint: $11.68) Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson
The stock's current P/E of 21.6x is notably higher than the company's historical fair value multiple of 17.0x Johnson & Johnson (JNJ) - Sure Dividend. This multiple expansion is the primary driver of the stock's current overvaluation.
Detailed Analysis
To determine the true intrinsic value of JNJ, we must triangulate its valuation using five distinct methodologies.
1. Discounted Cash Flow (DCF) Analysis
The DCF model estimates the present value of JNJ's future free cash flows (FCF). In Q2 2026, JNJ generated approximately $8.7 billion in free cash flow Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson.
- Inputs:
- Base Year FCF: $22.0 Billion
- Projected 5-Year FCF Growth Rate: 6.0% Johnson & Johnson (JNJ) - Sure Dividend
- Discount Rate (WACC): 8.0% Johnson & Johnson (JNJ) Revenue Model & Fair Value | R40
- Terminal Growth Rate: 2.5%
- Calculation: Discounting the next five years of cash flows yields a present value of approximately $95 billion. Calculating the terminal value (assuming 2.5% perpetual growth discounted at 8.0%) and discounting it to the present adds roughly $380 billion. Adding cash of $20.4 billion jnj-20260628 and subtracting debt gives an implied equity value of ~$465 billion.
- Implied Fair Value: $193.75 per share (assuming ~2.4 billion shares outstanding).
2. P/E Multiple Analysis
This relative valuation method compares JNJ's forward earnings against its historical trading multiples.
- Inputs:
- 2026 Adjusted EPS: $11.68 (management's raised guidance midpoint) Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson
- Target P/E Multiple: 17.0x (historical average for JNJ's mature growth profile) Johnson & Johnson (JNJ) - Sure Dividend
- Calculation: $11.68 × 17.0
- Implied Fair Value: $198.56 per share.
3. PEG Ratio Analysis
The Price/Earnings-to-Growth (PEG) ratio factors in the company's expected earnings growth rate to determine if the P/E ratio is justified.
- Inputs:
- Current P/E: 21.6x
- 5-Year Expected Growth Rate: 6.0% Johnson & Johnson (JNJ) - Sure Dividend
- Calculation: 21.6 / 6.0 = 3.6x PEG Ratio.
- Analysis: A PEG ratio of 1.0 is traditionally considered fair value. A PEG of 3.6x indicates severe overvaluation relative to the company's mid-single-digit growth prospects. To achieve a more reasonable PEG of 2.0x to 2.5x (standard for wide-moat mega-caps), the stock would need to trade closer to $175.00.
4. EV/EBITDA Valuation
Enterprise Value to EBITDA provides a capital-structure-neutral view of the company's operating cash yield.
- Inputs:
- Projected Terminal Year EBITDA: $49.08 Billion Johnson & Johnson (JNJ) Revenue Model & Fair Value | R40
- Target Exit Multiple: 13.0x Johnson & Johnson (JNJ) Revenue Model & Fair Value | R40
- Calculation: Applying a 13.0x multiple to normalized forward EBITDA aligns with a terminal enterprise value of roughly $638 billion Johnson & Johnson (JNJ) Revenue Model & Fair Value | R40. Adjusted for net debt, this translates to an equity value per share in the low $200s.
- Implied Fair Value: $205.00 per share.
5. Dividend Discount Model (DDM)
Because JNJ is a legendary dividend payer with 64 consecutive years of dividend increases Johnson & Johnson (JNJ) - Sure Dividend, the DDM is highly relevant.
- Inputs:
- Annualized Dividend: $5.36 ($1.34 quarterly) Johnson & Johnson (JNJ) - Sure Dividend
- Expected Dividend Growth Rate: 5.5%
- Cost of Equity (Discount Rate): 8.2%
- Calculation: Next year's expected dividend ($5.65) / (0.082 - 0.055)
- Implied Fair Value: $209.25 per share.
Bull Case
The bullish argument for JNJ centers on its exceptional operational execution in 2026. In Q2 2026, the Innovative Medicine unit grew 7.8% to $16.38 billion Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength. This was heavily driven by the blood cancer treatment Darzalex, which generated $4.2 billion in the quarter, and the immunology drug Tremfya, which surged 72.5% year-over-year to $2 billion Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength.
Furthermore, management's confidence is palpable. They raised 2026 guidance, projecting that annual revenue will cross the $100 billion mark for the first time in the company's 140-year history, landing at an estimated $101.1 billion Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson. Bulls argue that JNJ's wide economic moat and dominance in oncology justify a premium P/E multiple above 20x.
Bear Case
The bear case focuses heavily on valuation risk and looming patent cliffs. At $252, the stock is priced for perfection. If the P/E multiple compresses from its current 21.6x back to its historical average of 17.0x, investors could suffer a -4.7% annualized drag on returns through 2031 Johnson & Johnson (JNJ) - Sure Dividend.
Operationally, JNJ still faces the ongoing Stelara patent cliff headwind Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar. Additionally, the MedTech division is experiencing temporary weakness due to the narrowed use of Impella heart pumps, which will lack updated Protect-IV study data until 2027 Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar. If Innovative Medicine growth slows, there is little margin of safety at current prices.
Key Metrics Summary
| Metric | Current (July 2026) | Target / Historical |
|---|---|---|
| Stock Price | $252.00 | $190.00 - $199.00 |
| Market Cap | $606 Billion | N/A |
| Forward P/E | 21.6x | 17.0x |
| Dividend Yield | 2.1% | 2.5% - 3.0% |
| 2026 Revenue Guidance | $101.1 Billion | N/A |
| 2026 Adj. EPS Guidance | $11.68 | N/A |
| 5-Year Growth Est. | 6.0% | N/A |
Frequently Asked Questions
Why did Johnson & Johnson raise its 2026 guidance?
JNJ raised its 2026 guidance following a strong Q2 where revenue grew 6.6% to $25.3 billion Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson. The outperformance was driven by massive market share gains in its oncology and immunology portfolios, specifically the drugs Darzalex and Tremfya Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar.
Is JNJ's dividend safe at current levels?
Yes, the dividend is exceptionally safe. In April 2025, JNJ increased its dividend for the 64th consecutive year Johnson & Johnson (JNJ) - Sure Dividend. The company generated ~$8.7 billion in free cash flow in Q2 2026 alone [Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson](https://investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook], easily covering its dividend obligations.
What do major research firms consider the fair value of JNJ?
Independent research firms align closely with our intrinsic value calculations. Morningstar currently maintains a fair value estimate of $190.00 per share Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility | Morningstar, while Sure Dividend calculates a fair value price of $199.00 Johnson & Johnson (JNJ) - Sure Dividend.
Final Verdict
Johnson & Johnson is a phenomenal, wide-moat business executing flawlessly, as evidenced by its path to $100+ billion in 2026 revenue. However, a great company is not always a great stock.
At $252 per share, JNJ is overvalued by approximately 25% to 30%. The current valuation requires a 21.6x earnings multiple, which leaves investors vulnerable to multiple compression. Based on DCF, P/E, and DDM models, the intrinsic fair value of JNJ stock is firmly in the $190.00 to $199.00 range. Value-conscious investors should wait for a broader market pullback to initiate or add to positions at a more favorable margin of safety.
Ready to Analyze Your Next Investment?
Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.
Want full access to our institutional research tools? Explore Invest Daily Pro.
You're learning how to value stocks. Now apply it to any ticker in seconds.
Enter any ticker and our engine runs a DCF model, compares P/E to industry medians, and gives you an intrinsic value range with a margin of safety estimate.
Watch: Related Videos
from Invest DailyGet This Analysis in Your Inbox Every Morning
Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.
Essential Reading: Top Investor Guides
Our most comprehensive guides - start here to build a complete investing foundation.
Market Basics
Stock Market Fundamentals: How Markets Work, Reading Charts, and Technical Analysis
Portfolio Strategy
Portfolio Management Masterclass: Asset Allocation, Diversification, and Rebalancing
Retirement
The Complete Retirement Planning Guide: 401(k), IRA, Roth, and FIRE Strategy
Dividend Income
The Ultimate Guide to Dividend Investing: How to Build a Safe Income Portfolio
Valuation
The Complete Guide to Stock Valuation: How to Calculate Intrinsic Value
Financial Statements
How to Read a Balance Sheet Like a Professional Analyst
Monetary Policy
Understanding the Federal Reserve: How Monetary Policy Actually Works
Real Estate
Real Estate Investment Trusts (REITs): A Complete Investor's Guide
Options & Hedging
Options Basics: How to Use Derivatives to Protect Your Portfolio
Investor Psychology
